Arog Pharmaceuticals, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2010-01-01

Employees: 20

Market Cap: -

Website: http://www.arogpharma.com

Clinical Trials

Individual Patient Compassionate Use of Crenolanib

Conditions: FLT3-ITD Mutation
FLT3/TKD Mutation
PDGFR-Alpha D842V
PDGFRA Gene Amplification

First Posted Date: 2018-08-08

Last Posted Date: 2024-08-09

Lead Sponsor: Arog Pharmaceuticals, Inc.

Registration Number: NCT03620318

Locations: 🇮🇹
Ospedale Policlinico San Martino, Genova, Italy

A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

Phase 2

Withdrawn

Conditions: Relapsed/Refractory FLT3-mutated AML

Interventions: Drug: Crenolanib
Drug: Fludarabine
Drug: Cytarabine

First Posted Date: 2017-10-27

Last Posted Date: 2019-01-10

Lead Sponsor: Arog Pharmaceuticals, Inc.

Registration Number: NCT03324243

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Phase 3

Recruiting

Conditions: Newly Diagnosed FLT3 Mutated AML

Interventions: Drug: Crenolanib
Drug: Midostaurin
Drug: Cytarabine
Drug: Duanorubicin

First Posted Date: 2017-08-23

Last Posted Date: 2020-05-22

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 510

Registration Number: NCT03258931

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States
🇺🇸
Cornell University, New York, New York, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States

and more 28 locations

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Phase 3

Recruiting

Conditions: Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Interventions: Drug: Crenolanib
Drug: Cytarabine
Drug: Placebo Oral Tablet
Drug: Mitoxantrone
Drug: Fludarabine
Drug: Idarubicin
Drug: G-CSF

First Posted Date: 2017-08-15

Last Posted Date: 2021-04-30

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 322

Registration Number: NCT03250338

Locations: 🇺🇸
Kansas University, Kansas City, Kansas, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇨🇦
University of Alberta, Edmonton, Alberta, Canada

and more 59 locations

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Phase 1

Completed

Conditions: Esophagogastric Adenocarcinoma

Interventions: Drug: Crenolanib
Drug: Ramucirumab
Drug: Paclitaxel

First Posted Date: 2017-06-21

Last Posted Date: 2020-07-20

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 30

Registration Number: NCT03193918

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

Phase 3

Conditions: GIST With D842V Mutated PDGFRA Gene

Interventions: Drug: Placebo
Drug: Crenolanib

First Posted Date: 2016-07-28

Last Posted Date: 2021-01-22

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 120

Registration Number: NCT02847429

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States

and more 20 locations

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

Phase 2

Completed

Conditions: Recurrent/Refractory Glioblastoma

Interventions: Drug: crenolanib

First Posted Date: 2015-12-10

Last Posted Date: 2020-07-20

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 11

Registration Number: NCT02626364

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Phase 1

Completed

Conditions: Relapsed/Refractory Acute Myeloid Leukemia (AML)

Interventions: Drug: Crenolanib
Drug: Mitoxantrone
Drug: Cytarabine
Drug: Fludarabine
Drug: Etoposide
Drug: G-CSF
Drug: Idarubicin

First Posted Date: 2015-12-10

Last Posted Date: 2023-12-20

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 16

Registration Number: NCT02626338

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Houston Methodist, Houston, Texas, United States
🇺🇸
University of Arkansas, Little Rock, Arkansas, United States

and more 1 locations

Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Crenolanib besylate

First Posted Date: 2015-03-27

Last Posted Date: 2023-12-18

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 30

Registration Number: NCT02400255

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Crenolanib besylate
Drug: Idarubicin
Drug: Azacytidine
Drug: Cytarabine
Drug: Mitoxantrone
Drug: Etoposide
Drug: Fludarabine
Drug: G-CSF

First Posted Date: 2015-03-27

Last Posted Date: 2024-07-03

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 28

Registration Number: NCT02400281

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy